Promotional Labeling and Advertising Considerations for Prescription B – fda.gov

Promotional Labeling and Advertising Considerations for Prescription B  fda.govHow Are Global Regulatory Agencies Adjusting Their Policies for Biosimilars?  PharmExec.comBiosimilars Relief in Sight for Interchangeable Access  Pharmacy Practice NewsFDA finalizes guidance on promotional materials for biologics and biosimilars  Fierce PharmaFDA Guidance On Biosimilars Highlights Glycosylation Profiling And Increases The Strategic Value Of Patents Covering Antibodies Defined By Glycosylation  Mondaq